<DOC>
	<DOCNO>NCT02293720</DOCNO>
	<brief_summary>A multi-center , single-arm , open-label study evaluate safety effectiveness EndoBarrier Gastrointestinal Liner System liner glycemic control control subject study # 09-1 treatment failure complete 12 month study .</brief_summary>
	<brief_title>An Open-Label Extension Protocol 09-1 , Efficacy Safety Study EndoBarrier® Gastrointestinal Liner System</brief_title>
	<detailed_description>This open-label extension study subject participate control arm study # 09-1 ( A Randomized , Multi-Center , Pivotal Efficacy Safety Study Comparing EndoBarrier Gastrointestinal Liner System vs. Sham Glycemic Improvement Inadequately Controlled Obese Type 2 Diabetic Subjects Oral Anti-Diabetes Agents ) treatment failure complete 12 month study .</detailed_description>
	<criteria>1 . Control subject study # 091 treatment failure complete 12 month study 2 . Age ≥21 year ≤ 65 year 3 . Have sign inform consent form within 30 day week 52 visit study # 091 . 4 . HbA1c ≥ 7.5 % ≤ 10 % 5 . Stable ( ) dose ( 2 ) anti diabetes medication ( ) minimum 3 month prior enrollment least one minimum require dose outline : 1 . MET ( ≥1500 mg/day ) OR 2 . SU ( base dos specify ) Generic Name ( brand name ) minimum require dose Glimepiride ( Amaryl ) 4 ( mg/day ) Glipizide ( Glucotrol ) 20 ( mg/day ) Glipizide ( Glucotrol XL ) 10 ( mg/day ) Glyburide ( Micronas , Diabeta ) 10 ( mg/day ) Micronized Glyburide ( Glynase ) 6 ( mg/day ) Chlorpropamide ( Diabinese ) 350 ( mg/day ) Tolazamide ( Tolinase 500 ( mg/day ) Tolbutamide ( Orinase ) 1500 ( mg/day ) OR 3 . DPP4i ( base dos specify ) Generic Name ( brand name ) minimum require dose Sitagliptin ( Januvia® ) 50 ( mg/day ) Saxagliptin ( Onglyza® ) 2.5 ( mg/day ) Linagliptin ( Tradjenta ® ) 5 ( mg/day ) Alogliptin ( Nesina® ) 12.5 ( mg/day ) 4 . TZD ( base dos specify ) Generic Name ( brand name ) minimum require dose Rosiglitazone ( Avandia® ) 4 ( mg/day ) Pioglitazone ( Actos® ) 30 ( mg/day ) 6 . BMI ≥ 30 ≤ 55 7 . Willing comply study requirement 8 . Documented negative pregnancy test woman childbearing potential 9 . Women childbearing potential intending become pregnant duration trial participation Exclusion Criteria 1 . Any change subject 's previous health status assessment eligibility pivotal trial phase ( new condition major illness ) place subject undue risk participate study 2 . Cpeptide &lt; 1.0 ng/mL 3 . Triglyceride level &gt; 400 mg/dL 4 . Vitamin D deficiency ( &lt; 20ng/ml ) 5 . Male subject serum Cr &gt; 1.5 mg/dl female subject Cr &gt; 1.4 mg/dl 6 . Uncorrectable bleed diathesis , platelet dysfunction , thrombocytopenia platelet count less 100,000/microliter , know coagulopathy 7 . Symptomatic kidney stone gallstone within 6 month prior baseline ( within 30 day week 52 visit # 091 study ) 8 . Acute pancreatitis time baseline ( within 30 day week 52 visit # 091 study ) 9 . Diagnosis osteoporosis currently take bisphosphonates teriparatide 10 . Currently take NonSteroidal AntiInflammatory Drugs ( NSAIDs ) ( e.g . aspirin , ibuprofen , etc . ) within 10 day procedure and/or need expect need use trial 12 month post index procedure 11 . Currently take prescription antithrombotic therapy ( e.g . anticoagulant antiplatelet agent ) within 10 day prior procedure and/or need expect need use trial 12 month post index procedure 12 . Currently take follow medication ( time enrollment ) and/or need expect need use medication trial 12 month post index procedure : Restricted Medications/Supplements Systemic corticosteroid Drugs know affect GI motility ( e.g . Reglan ) Prescription overthecounter weight loss medication ( ) Medications know cause significant weight gain ( refer study reference manual ( SRM ) weight loss ( e.g . chemotherapeutics ) 13 . Currently take ≥ two follow medication type 2 diabetes ; MET , SU , DDP4i TZD baseline ( within 30 day week 52 visit # 091 study ) 14 . Currently take medication type 2 diabetes MET , SU , DPP4i , TZD ( e.g . GLP1 insulin ) baseline ( within 30 day week 52 visit # 091 study ) 15 . Chronic use narcotic , opiate , benzodiazepine addictive tranquilizer 16 . Allergy hypersensitivity ceftriaxone , cephalosporin , penicillin , equivalent antibiotic 17 . Active H. pylorus ( Note : Subjects may eligible undergo 2 week antibiotic treatment without rescreening ) 18 . Residing location without ready access study site medical resource 19 . Documented weight loss &gt; 10 pound anytime 3 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>